Genflow Biosciences reports positive anti-ageing dog trial results
(Alliance News) - Genflow Biosciences PLC on Tuesday said results from a clinical trial showed its anti-ageing gene therapy reduced the biological age of elderly dogs.
The London-based biotechnology company specialising in treatments for age-related diseases said its trial in aged beagles met its main target, with treated animals showing an improvement compared with those that did not receive the treatment.
The randomised, blinded trial enrolled 24 beagles aged over 10 years. They were divided into four groups. Two groups received different doses of Genflow's SIRT6 gene therapy as naked DNA, while a third received the same gene therapy delivered using AAV8, a virus used to carry genetic material into cells. The fourth group received a saline solution instead of the treatment and served as a control.
Researchers measured the beagles' biological age using the GRIM methylation clock, which analyses DNA methylation changes associated with ageing to estimate biological age.
Genflow said the results support the potential of its SIRT6 gene therapy to treat age-related decline in companion animals.
The company said it is in talks with major animal health companies about licensing the treatment or working together to develop and commercialise it.
Genflow said the results build on preliminary muscle data reported in February.
The company said it saw improvements across several other measures of the dogs' health and function. It will present detailed results from the trial at the Animal Longevity Summit in Toronto in October.
Eric Leire, chief executive officer of Genflow Biosciences, said: "Meeting the primary endpoint in SLAB is a defining milestone for Genflow. We set out to demonstrate that our centenarian SIRT6 naked DNA therapy could measurably address age-related decline in a real-world aging mode. This provides a powerful foundation for our partner discussions across animal health. We look forward to sharing the full dataset, including the critical methylation clock and muscle histology results, with the scientific and investment communities at the Animal Longevity Summit in October."
Shares in Genflow Biosciences were up 1.6% at 2.50 pence per share on Tuesday afternoon in London.
By Niall Holden, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
United States